The application of real world study in the safety evaluation of Chinese patent medicine after marketingQIAO Jia-hui, YANG Pu, DONG Li, MENG Ling-quan, HUANG Zhe, CHEN Yu-wen769-772
Strategies for development of probiotic preparations and construction of related quality standardsXING Sheng, WANG Shu-hua, HU Wen-hong, SHEN Zhen, REN Li-hong, DING Bo773-779
Construction and thinking of clinical evaluation system in accordance with the characteristics of traditional Chinese medicineGAO Rui780-783
The influence of USA risk evaluation and mitigation strategy on the reference listed drug of generic product in ChinaYANG Dong-sheng, NIU Jian-zhao, XU Ming-di784-790
Research progress in neurological safety evaluation of nanomedicinesQU Zhe, HUO Gui-tao, LIN Zhi, L(U) Jian-jun, YANG Yan-wei, ZHANG Di, LI Bo, GENG Xing-chao791-796
Sodium-glucose co-transporter 2 inhibitors:research progress on pharmacological actions and clinical useZHAO Mei, CHEN Li-na, HUANG Lin, FENG Yu-fei797-802
Consensus of Chinese experts for the treatment of non-small cell lung cancer with icotinib (2021 version))SHI Yuan-kai803-808
Analysis on reasons and countermeasures of exfoliated cases in bioequivalence clinical trialTIAN Yan, SUI Xin, CAO Ying, CHEN Lu, MA Ke-ji, WANG Hua-wei, WANG Wen-ping809-813
Value and considerations of central laboratory in drug clinical trialsFAN Hua-ying, XIE Zhen-wei, WANG Li-jue, RAO Hui-ying814-817
Anti-inflammatory effect and its mechanism of national medicine Laggera alata(D.Don) Sch.Bip.ex OlivWEI Jiang-cun, QIN Zu-jie, ZHONG Wen, LI Yao-hua, XIE Pei-tao, YANG Peng, QIN Li-ping, ZHAO Feng-xian, HAN Qian818-823